VEGF inhibitors for the treatment of neovascular age-related macular degeneration

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.18, Iss.5, 2009-05, pp. : 637-646

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-VEGF Compounds in the Treatment of Neovascular Age Related Macular Degeneration

Current Drug Targets, Vol. 12, Iss. 2, 2011-01 ,pp. : 173-181

Bentham Science Publishers

Access to resources Recommend Favorite

Pegaptanib sodium for the treatment of neovascular age-related macular degeneration

By Moshfeghi Andrew A Puliafito Carmen A

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 5, 2005-05 ,pp. : 671-682

Informa Healthcare

Access to resources Recommend Favorite

An update on the pharmacotherapy of neovascular age-related macular degeneration

By Freund K Bailey Mrejen Sarah Gallego-Pinazo Roberto

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 8, 2013-06 ,pp. : 1017-1028

Informa Healthcare

Access to resources Recommend Favorite

Neovascular Age-Related Macular Degeneration: Potential Therapies

By Chappelow Aimee V. Kaiser Peter K.

Drugs, Vol. 68, Iss. 8, 2008-01 ,pp. : 1029-1036

Adis International

Access to resources Recommend Favorite

Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration

By Stewart Michael W

Expert Review of Clinical Pharmacology, Vol. 6, Iss. 2, 2013-03 ,pp. : 103-113

Informa Healthcare

Access to resources Recommend Favorite